Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth.
J Cell Mol Med
; 25(5): 2645-2654, 2021 03.
Article
em En
| MEDLINE
| ID: mdl-33523587
ABSTRACT
Anwulignan is a monomer compound derived from Schisandra sphenanthera lignans. It has been reported to possess a spectrum of pharmacological activities, including anti-bacterial, anti-inflammatory, anticancer and hepatoprotective properties. However, its anticancer capacity and molecular mechanism(s) against non-small cell lung cancer (NSCLC) have not been fully elucidated. Anwulignan significantly inhibited cell growth and increased G1-phase cell cycle arrest in NSCLC cells. Anwulignan strongly attenuates the JAK1/STAT3 signalling pathway by directly targeting JAK1 protein kinase activity in vitro. The anticancer activity by Anwulignan is dependent upon the JAK1 protein expression. Remarkably, Anwulignan strongly inhibited tumour growth in vivo. In conclusion, Anwulignan is a novel JAK1 inhibitor that may have therapeutic implications for NSCLC management.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Schisandra
/
Inibidores de Proteínas Quinases
/
Janus Quinase 1
/
Antineoplásicos Fitogênicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Cell Mol Med
Assunto da revista:
BIOLOGIA MOLECULAR
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
China